Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

June 23rd 2022, 7:41pm


Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.

FDA Accepts Futibatinib for Priority Review for FGFR2 Rearrangements and Fusions in Cholangiocarcinoma

March 30th 2022, 7:08pm


Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.

AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC

February 25th 2022, 11:30pm


Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).

Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting

February 23rd 2022, 11:50pm


This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.

Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study

February 18th 2022, 12:15pm


A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.

Improvement Needed for Liquid Biopsy to Have Clinical Utility in Lung Cancer

February 15th 2022, 11:00pm


This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.

More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM

February 12th 2022, 12:00pm


This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

ctDNA Detection in RCC Requires More Sensitive Detection Methods

February 8th 2022, 7:00pm


Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

Liquid Biopsy May Have Prognostic, Theranostic Benefits in PDAC

February 5th 2022, 7:00pm


Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.

Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer

February 2nd 2022, 9:45pm


Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).